Influence of Atrial Fibrillation on Two-Year Survival of Patients with Implanted Cardioverter Defibrillator

Group		Sinus rhythm	Atrial fibrillation	p
Number(%)		99 (47,1%)	111 (52,9%)
Age (years)		67,7 ± 11,3	67,7 ± 9,6	p=0,517^a
Gender	Man	68 (68,7%)	78(70,3%)	p=0.062^b
Gender	Woman	31 (31,3%)	33 (29,7%)	p=0.062^b
Hypertension		77,8%	88,3%	p=0.064^b
Diabetes mellitus		41,4%	28,8%	p=0.056^b
Hyperlipidemia		65,6%	60,0%	p=0.399^b
Smoking		27,3%	21,6%	p=0.340^b
Heredity		27,2%	21,6%	p=0.340^b

a Т test,

b Хi square test,

* significance level 0.05

Table 2.

Value of laboratory parameters between compared groups

Group		Sinus rhythm	Atrial fibrillation	p
NT-proBNP (pg/mL)	Mean ± SD	4037.5 ± 5474.5	4852.3 ± 6645.1	p=0.177^c
NT-proBNP (pg/mL)	Median	1519.5	2036	p=0.177^c
Troponin (pg/mL)	Mean ± SD	0.065 ± 0.138	0.065±0.20	p=0.978^c
Troponin (pg/mL)	Median	0.019	0.019	p=0.978^c
Hemoglobin (g/L)	Mean ± SD	125.1 ± 18.5	129.4 ± 22.9	p=0.113^c
Hemoglobin (g/L)	Median	129	132	p=0.113^c
CRP (mg/L)	Mean ± SD	8.39 ± 12.28	8.33 ± 10.8	p=0.815^c
CRP (mg/L)	Median	4.95	4.20	p=0.815^c
Urea (mmol/L)	Mean ± SD	9.00 ± 4.01	8.38 ± 4.25	p=0.362^c
Urea (mmol/L)	Median	8.15	7.6	p=0.362^c
Creatinine (µmol/L)	Mean ± SD	125.9 ± 157.5	114.1 ± 52.0	p=0.104^c
Creatinine (µmol/L)	Median	96	104	p=0.104^c
Na+ (mmol/L)	Mean ± SD	139.6 ± 3.8	135.42 ±14.25	p=0.794^c
Na+ (mmol/L)	Median	140	140	p=0.794^c

c Mann-Whitney test

* significance level 0.05

Table 3.

Prevalence of cardiovascular drug groups in patient groups.

Group	Sinus rhythm	Atrial fibrillation	p
Amiodarone	49.5%	68.5%	p=0.005^b, ^*
Beta blocker	84.5%	91.0%	p=0.154^b
ACE inhibitor	74.7%	71.2%	p=0.481^b
Anticoagulant therapy	61.0%	95.5%	p=0.000^b, ^*
ASA	56.1%	25.2%	p=0.000^b, ^*
Thienopyridine	19.1%	9.0%	p=0.028^b, ^*
Statin	67.7%	58.6%	p=0.143^b

b Хi square test,

* significance level 0.05

Table 4.

Prevalence of associated cardiovascular diseases.

Group	Sinus rhythm	Atrial fibrillation	p
Ischemic heart disease	60.6%	35.1%	p=0.000^b, ^*
Non-ischemic heart disease	39.4%	64.9%	p=0.000^b, ^*
Peripheral artery disease	21.2%	9.9%	p=0.023^b, ^*
Cerebrovascular event	5.0%	14.4%	p=0.024^b, ^*
Chronic renal failure	7.1%	10.8%	p=0.346^b

b Хi square test,

* significance level 0.05

Table 5.

Distribution of patients with ICD activation between the compared groups.

Group	Sinus rhythm	Atrial fibrillation	p
Number of patients with ICD activation	16 (16.2%)	23 (20.7%)	P=0.396^b

b Хi square test

* significance level 0.05

Types of activation of the implanted cardioverter defibrillator.

Table 6.

Distribution of types ICD activation between the groups.

Group	Sinus rhythm	Atrial fibrillation	P
Incidence of appropriate ICD activation	16 (48.5%)	17 (51,5%)	p=0.863^b
Incidence of inappropriate ICD activation	3 (21,4%)	11 (78,6%)	P=0.046^b*

References

Authors

Metrics

Articles in this issue

DOI: https://doi.org/10.2478/sjecr-2022-0035 | Journal eISSN: 2956-2090 (formerly 2335-075X, 2956-0454) | Journal ISSN: 2956-0454 (formerly 1820-8665)

Journal RSS Feed

Language: English

Page range: 259 - 266

Submitted on: Feb 5, 2022

Accepted on: Feb 19, 2022

Published on: Nov 23, 2022

Published by: University of Kragujevac, Faculty of Medical Sciences

In partnership with: Paradigm Publishing Services

Keywords:

Atrial fibrillation,

implantable cardioverter defibrillator,

ICD,

Related subjects:

Clinical medicine, other

© 2022 Vladimir Ignjatović, Ivana Đokić-Nikolić, Stefan Simović, Bojana Đoković, Ema Jevtić, Zorica Smiljanić, Vesna Ignjatović, published by University of Kragujevac, Faculty of Medical Sciences
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Volume 25 (2024): Issue 3 (September 2024)

Influence of Atrial Fibrillation on Two-Year Survival of Patients with Implanted Cardioverter Defibrillator

Figures & Tables

Table 1.

Table 2.

Table 3.

Table 4.

Figure 1.

Table 5.

Figure 2.

Table 6.

Paradigm

My account